Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer

NCT01360853 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT01360853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01360853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2015
Enrollment
160 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma